MyMetabolon Login
© 2020 Metabolon, Inc. All rights reserved.
Metabolon Metabolon
  • Metabolomics
    • About Metabolomics
    • Our Process
    • Technology & Knowledgebase
    • Setting the Standard: The 4Cs
    • Our Latest Insights
  • Solutions
    • Column 1
      • Products & Services
        • Global Metabolomics
        • Lipidomics
        • Targeted Assays
        • Study Design & Consulting
        • Sample Preparation & Handling
        • Study Success Sample Handling Kit
        • Reporting & Interpretation
        • Bioinformatics
        • MyMetabolon Client Portal
    • Column 2
      • By Research & Development Phase
        • Discovery & Target Selection
        • Lead Candidate Selection
        • Preclinical
        • Clinical Development
        • Manufacturing & Bioprocessing
    • Column 3
      • By Therapeutic Area
        • Cardiovascular Disease
        • COVID-19
        • Diabetes
        • Gastrointestinal
        • Liver Disease
        • Microbiome
        • Neuroscience
        • Oncology
        • Renal & Urological Disorders
        • Respiratory Disorders
    • Column 4
      • By Sector
        • Academic
        • Agriculture
        • Biotech / Pharmaceutical
        • Precision Medicine
        • Nutrition
        • Personal Care & Cosmetics
        • Population Health
        • Veterinary & Animal Health
  • Insights
    • Our Latest Insights
    • Blog
    • News & Events
  • Resources
    • Resource Library
    • Client Stories
    • COVID-19
  • Company
    • About Us
    • Working With Us (FAQ)
    • Leadership
    • Careers
    • Strategic Partnering
    • News & Events
    • Contact Us
MyMetabolon
Demo Our Data
Metabolon
Demo Our Data

Go With Your Gut: Metabolomics & the Microbiome

inMicrobiome, Population Health

While diet is thought to be one of the most important, variable determinants of an individual’s health, our overall health is also heavily influenced by the gut microbiome, a population of microorganisms living throughout an individual’s digestive system.2 Unfortunately, much about digestive diseases remains a mystery. For example, irritable bowel syndrome (IBS) is estimated to impact between 25 and 45 million Americans. Although its exact cause is unknown,3 diet and microbiome are recurring influences.

According to the National Institutes of Health (NIH), there are approximately 60 to 70 million people in the U.S. affected by some type of digestive disease.1 Digestive disease refers to a broad range of gastrointestinal-related health issues, ranging from chronic constipation to gastrointestinal infections to viral hepatitis. With so many affected people and an estimated cost of $141.8 billion in the U.S., the unmet need to help diagnose and care for these patients is clear.1

Understanding the underlying biology of chronic diseases, like IBS, is important in identifying the biomarkers that will help spur early disease detection and, potentially, prevention. Enter Precision Metabolomics™, an essential technology for investigating the role that diet and the microbiome play in health, health maintenance and disease – and it can be even more important in complex diseases where the drivers are numerous and diverse (e.g., genetics, environment and microbiota).

The microbiome performs essential functions that are critical to our health, including immune system development and homeostasis, manufacturing nutrients such as vitamins and hormones, metabolizing drugs and harvesting energy from the diet. Changes to the human microbiome, also known as dysbiosis, or a microbial imbalance on or inside the body have been shown to be key factors in a surprisingly wide variety of diseases such as allergies, arthritis, asthma, autism, colon cancer, C. difficile infections, diabetes, IBS, obesity and many others.

Metabolomics can help answer important questions for digestive health, including:

•    What effect does a nutrient have?
•    How does diet affect markers of disease?
•    How much is needed for the desired effects?
•    How safe are nutrients at efficacious levels?
•    How do diet and the microbiome interact to influence health?

We encourage you to explore some of Metabolon’s publications to help understand the role of metabolomics in digestive health and microbiome research. Through this research, the microbiome is becoming more understood, and our definition of what is normal, or even healthy, is constantly evolving. Metabolon’s studies are going far beyond assessments of customary metabolite measurements, such as glucose and cholesterol, to evaluate the influences of genes, diet and lifestyle, microbiome and drug treatment on health.

References

  1. National Institute of Health. Digestive Diseases Statistics for the United States. Available at https://www.niddk.nih.gov/health-information/health-statistics/Pages/digestive-diseases-statistics-for-the-united-states.aspx. Accessed 04-11-2017.
  2. Turnbaugh PJ, Ridaura VK, Faith JJ, Rey FE, Knight R, Gordon JI. The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Sci Transl Med. 2009;1(6):6ra14.
  3.  International Foundation for Functional Gastrointestinal Disorders. Facts about IBS. Available at http://www.aboutibs.org/what-is-ibs/facts-about-ibs-2.html. Accessed 04-11-2017.
Back to the Blog
  • Metabolomics Needs Precision: The Case for Mass Spectrometry
    Previous PostMetabolomics Needs Precision: The Case for Mass Spectrometry
  • Next PostMetformin & Metabolism: Beyond Diabetes
    Metabolomics Needs Precision: The Case for Mass Spectrometry

Related Posts

Webinar: Unique advantages of incorporating untargeted and targeted metabolomics in drug development and clinical trials
Events

Webinar: Unique advantages of incorporating untargeted and targeted metabolomics in drug development and clinical trials

Leveraging Machine Learning to Advance Precision Medicine
Press

Leveraging Machine Learning to Advance Precision Medicine

National Institute of Allergy and Infectious Disease (NIAID) Selects Metabolon, Inc. for COVID-19 Study
Company News

National Institute of Allergy and Infectious Disease (NIAID) Selects Metabolon, Inc. for COVID-19 Study

Webinar: Deeper Understanding of COVID-19 Phenotypes Through Metabolomics: A Panel Discussion
Events

Webinar: Deeper Understanding of COVID-19 Phenotypes Through Metabolomics: A Panel Discussion

Metabolon’s Client Data Table enables study analysis
Blog Capabilities Working with Metabolon

Metabolon’s Client Data Table enables study analysis

Establishing industry QA/QC best practices for global metabolomics
Capabilities Working with Metabolon

Establishing industry QA/QC best practices for global metabolomics

Webinar: Mechanisms of Immune Control and Metabolomics
Events

Webinar: Mechanisms of Immune Control and Metabolomics

Metabolon, Inc. Announces $72 Million in Debt and Equity Financing to Accelerate Advancements in Precision Medicine and Innovative Drug Development Technologies
Company News

Metabolon, Inc. Announces $72 Million in Debt and Equity Financing to Accelerate Advancements in Precision Medicine and Innovative Drug Development Technologies

Event: BioProcess International
Events

Event: BioProcess International

Presentation: Leveraging Global Metabolomics at the Intersection of Physiology and Behavior (at MANA 2020)
Events

Presentation: Leveraging Global Metabolomics at the Intersection of Physiology and Behavior (at MANA 2020)

Metabolomics

  • About Metabolomics
  • Our Process
  • Technology & Knowledgebase
  • Setting the Standard: The 4Cs
  • Insights & Discoveries

Solutions

  • Products & Services
  • By Research & Development Phase
  • By Therapeutic Area
  • By Sector

Insights

  • Our Latest Insights
  • Blog
  • News & Events

Resources

  • Resource Library
  • Client Stories
  • COVID-19

Company

  • About Us
  • Working With Us (FAQ)
  • Leadership
  • Careers
  • Strategic Partnering
  • News & Events
  • Contact Us
Metabolon - Logo - Enlightening Life

Metabolon provides actionable biological insights to answer the toughest questions in life sciences research and drug development.

© 2021 Metabolon, Inc. All rights reserved. Privacy & Terms

in
Copy
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Cookie settingsACCEPT
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.